CONTEXT Wogonoside has many pharmacological activities, but whether it has a protective effect against non-alcoholic fatty liver disease (NAFLD) has not been reported. OBJECTIVE This study investigates the protective effect of wogonoside against NAFLD in mice and its potential mechanism. MATERIALS AND METHODS C57BL/6 mice were randomly divided into control group, NAFLD group and low-, medium- and high-dose wogonoside groups (5, 10 and 20 mg/kg, respectively) (n= 12). Mice in the control group were fed with the standard diet, and those in NAFLD group and low-, medium- and high-dose wogonoside groups were fed with a high-fat diet. The different doses of wogonoside were administered by gavage once a day for 12 weeks. RESULTS Compared with those in NAFLD group, the liver mass, liver index and the LDL, TG, TC, IL-2, IL-6, TNF-α, MDA and NF-κB p65 levels were decreased, and the SOD and GSH-Px activities, and HDL, IκBα, Nrf2 and HO-1 contents were increased in wogonoside groups. Compared with those in the NAFLD group, wogonoside (5, 10 and 20 mg/kg) reduced AST (132.21 ± 14.62, 115.70 ± 11.32 and 77.94 ± 8.86 vs. 202.35 ± 19.58 U/L) and ALT (104.37 ± 11.92, 97.53 ± 10.12 and 56.74 ± 6.33 vs. 154.66 ± 14.23 U/L) activities in the serum. DISCUSSION AND CONCLUSIONS Wogonoside has a protective effect against NAFLD in mice, which may be related to its anti-inflammation and inhibition of oxidative stress, suggesting that wogonoside may be a potential therapeutic agent for the treatment of NAFLD.

中文翻译：

---

汉黄芩苷对非酒精性脂肪肝小鼠炎症反应和氧化应激的影响

背景Wogonoside 具有多种药理活性，但是否对非酒精性脂肪性肝病（NAFLD）具有保护作用尚未见报道。目的本研究探讨汉黄芩苷对小鼠NAFLD的保护作用及其潜在机制。材料与方法 C57BL/6 小鼠随机分为对照组、NAFLD 组和低、中、高剂量汉黄芩苷组（分别为 5、10 和 20 mg/kg）（n=12）。对照组小鼠喂食标准饲料，NAFLD组和低、中、高剂量伍戈诺苷组喂食高脂饲料。不同剂量的汉黄芩苷每天一次灌胃给药，持续 12 周。结果与NAFLD组相比，肝脏质量、肝脏指数及LDL、TG、TC、IL-2、IL-6、TNF-α、汉黄芩苷组MDA和NF-κB p65水平降低，SOD和GSH-Px活性，HDL、IκBα、Nrf2和HO-1含量升高。与 NAFLD 组相比，汉黄芩苷（5、10 和 20 mg/kg）降低了 AST（132.21 ± 14.62、115.70 ± 11.32 和 77.94 ± 8.86 vs. 202.35 ± 19.58 U/L, 413.7 ALT ±10.35） ± 10.12 和 56.74 ± 6.33 与 154.66 ± 14.23 U/L) 血清中的活性。讨论与结论Wogonoside对小鼠NAFLD具有保护作用，可能与其抗炎和抑制氧化应激有关，提示Wogonoside可能是治疗NAFLD的潜在治疗剂。10 和 20 毫克/公斤）降低 AST（132.21 ± 14.62、115.70 ± 11.32 和 77.94 ± 8.86 对比 202.35 ± 19.58 U/L）和 ALT（104.37 ± 11.92. 11.92. 16 ±16.58.86 和 16.58.58 U/L） /L) 血清中的活性。讨论与结论Wogonoside对小鼠NAFLD具有保护作用，可能与其抗炎和抑制氧化应激有关，提示Wogonoside可能是治疗NAFLD的潜在治疗剂。10 和 20 毫克/公斤）降低 AST（132.21 ± 14.62、115.70 ± 11.32 和 77.94 ± 8.86 对比 202.35 ± 19.58 U/L）和 ALT（104.37 ± 11.92. 11.92. 16 ±16.58.86 和 16.58.58 U/L） /L) 血清中的活性。讨论与结论Wogonoside对小鼠NAFLD具有保护作用，可能与其抗炎和抑制氧化应激有关，提示Wogonoside可能是治疗NAFLD的潜在治疗剂。